Evidence in Support of Potential Applications of Lipid Peroxidation Products in Cancer Treatment

Table 1

A summary of the effect of lipid peroxidation products (alone or in combination with cancer therapy) on cancer cells.

Type of cancer or tumor cells	Lipid peroxidation products	Summary of key findings	Reference
Leukemic cells	MDA	Enhanced the cytotoxicity of doxorubicin, vincristine, and fludarabine on leukemic cells	[57]
Colorectal adenocarcinoma cells	MDA	Enhanced the sensitivity of colorectal adenocarcinoma cells to radiotherapy	[58]
Lung carcinoma and glioblastoma cells	Acrolein	Inhibition of tumor growth	[59]
Renal cancer cells	Acrolein	Potentiation of TRAIL-induced apoptosis; downregulated expression of Bcl-2; ROS dependent upregulation of TRAIL death receptor 5	[60]
Prostate cancer cells	HNE	Potentiation of inhibiting effect of panobinostat; augmented G2/M arrest; enhanced DNA damage and cell death	[61]
Breast and mammary carcinoma cells	MDA	Inhibition of tumor growth	[65, 66]
Colon cancer cells	MDA	Increased DNA fragmentation; induction of apoptosis	[67]
Neuroblastoma cells	HNE	Inhibition of cell proliferation; reduction of S-phase cells; induction of apoptosis; upregulated expression of p53 tumor suppressor and target proteins	[78]
Leukemic and colon carcinoma cells	HNE	Inhibition of cell proliferation; downregulation of TERT expression and telomerase activity; inhibition of c-Myc expression; activation of Mad-1 expression; interference with DNA binding activity of c-Myc and Mad-1 to TERT promoter	[80, 81]

MDA: malondialdehyde; HNE: 4-hydroxynonenal; ROS: reactive oxygen species; TERT: telomerase reverse transcriptase; TRAIL: TNF-related apoptosis-inducing ligand.